When the market won’t move, policy can
At A Race Against Blindness, our mission is rooted in one simple truth: children facing progressive vision loss cannot afford for innovation to stall.
Through our work with families affected by rare, inherited retinal diseases, we’ve learned that progress isn’t driven by science alone. It’s also shaped by policy—and by whether systems are in place to encourage companies to invest in conditions that affect relatively small populations.
Developing a new medicine is expensive. It requires years of research, clinical trials, and regulatory review. For conditions that affect large patient populations, companies can often justify that investment.
But for rare pediatric diseases—including many that cause childhood-onset vision loss—the math often doesn’t work. Even when the science is promising and the need is urgent, treatments may be delayed or never developed at all.
This is where policy becomes a powerful tool.
And it’s why the Give Kids a Chance Act matters so deeply to the vision loss community.
The program behind the bill: What is a Priority Review Voucher?
The Give Kids a Chance Act is tied to a federal incentive known as the Rare Pediatric Disease Priority Review Voucher (PRV) program.
The concept is straightforward:
If a company successfully develops a treatment for a qualifying rare pediatric disease and that treatment receives FDA approval, the company may earn a Priority Review Voucher.
That voucher can then be used in one of two ways:
-
To speed up FDA review of another medicine the company is developing
-
Or to sell the voucher to another company, which can then use it to accelerate review of one of their own medicines
For companies working in rare disease—and especially in inherited retinal disease research—this incentive can help offset the enormous cost and risk involved in developing therapies for small patient populations.
And that matters, because time matters. Faster review can mean earlier access to treatments for children whose vision is actively changing.
Why this matters to the vision loss community
At A Race Against Blindness, we work with families living on a clock.
Many inherited retinal diseases are progressive. A child may be born with usable vision, only to lose it gradually over time. For families, this creates a unique kind of urgency—one measured not just in years, but in developmental milestones, independence, and opportunity.
Vision loss in childhood doesn’t only affect eyesight. It shapes how a child learns, navigates the world, and imagines their future.
Families don’t just need awareness. They need a pipeline of potential treatments.
They need systems that make it more likely that researchers and companies will choose to build therapies for rare vision conditions—rather than abandoning them due to financial or regulatory hurdles.
The Priority Review Voucher program is one of the mechanisms designed to help keep that pipeline moving.
What happened in 2024—and why families were alarmed
In December 2024, the rare pediatric disease voucher program reached a critical point.
Without congressional action, the program faced expiration. That raised serious concern across the rare disease and vision research communities. When incentives disappear, investment often follows—and promising therapies for childhood-onset vision loss risk being delayed, deprioritized, or discontinued.
For families already navigating uncertainty around their child’s sight, the potential loss of one of the few incentives supporting rare pediatric drug development was deeply concerning.
The update: Give Kids a Chance has been extended through 2029
There is encouraging news.
The Give Kids a Chance Act has since moved forward as part of federal legislation, extending the rare pediatric disease voucher program through September 2029.
For the vision loss community, this extension provides something critically important: continuity.
When incentives are predictable and long-term, companies are more likely to commit to retinal research programs, fund clinical trials, and carry therapies through the lengthy approval process. That stability increases the likelihood that treatments for rare vision conditions continue moving forward rather than stalling midstream.
A “homework pass” that can unlock real-world vision therapies
One helpful way to understand a Priority Review Voucher is to think of it as a “homework pass.”
A company takes on the hardest assignment—developing a treatment for a rare pediatric disease, including those that cause progressive vision loss—and earns something of real value in return. That reward can be used or traded, but either way, it creates a reason to invest in work that might otherwise be passed over.
The concept is simple. The impact is not.
For families watching vision change month by month, these policy decisions are not abstract. They influence whether research continues, whether trials are funded, and whether hope remains active rather than theoretical.
What you can do—even if you’re tired
If you’re part of the vision loss community—whether as a parent, caregiver, advocate, or supporter—and you’re already stretched thin: we see you.
Advocacy doesn’t have to mean doing everything. Sometimes it means doing one small thing that helps protect momentum:
-
Share this post to help others understand why policy matters for rare vision conditions
-
Stay informed about legislation that impacts rare disease and inherited retinal research
-
If you have the capacity, reach out to your elected officials and explain why incentives for rare pediatric vision loss matter—personal stories move policy
At A Race Against Blindness, our mission goes beyond fundraising. We exist to support the families, research, and systems working toward a future where children are not defined by the vision they lose—but by the lives they are able to build.
Kids deserve a chance.
And children facing vision loss deserve a future filled with possibility.
Sources
-
Rare Disease Legislative Advocates – Give Kids a Chance Act explainer
-
U.S. Food & Drug Administration – Rare Pediatric Disease Priority Review Voucher Program
-
U.S. Congress – Mikaela Naylon Give Kids a Chance Act (S.932)
-
National Organization for Rare Disorders (NORD) – Rare Pediatric Disease PRV Program
-
Fierce Pharma – Reporting on PRV program reauthorization through 2029
